Actively Recruiting

Phase Not Applicable
Age: 21Years - 65Years
All Genders
NCT06344481

The Hyalex First-in-Human Study

Led by Hyalex Orthopaedics, Inc. · Updated on 2025-06-29

15

Participants Needed

2

Research Sites

129 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

The Hyalex First-in-Human Study is a prospective, multicenter, open-label, single-arm, 2-phase, first-in-human study to evaluate the safety and technical performance of the HYALEX Knee Cartilage System for replacement of loss of articular cartilage and bone of the knee femoral condyles in symptomatic patients who require surgical treatment.

CONDITIONS

Official Title

The Hyalex First-in-Human Study

Who Can Participate

Age: 21Years - 65Years
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Age between 21 and 65 years
  • Body Mass Index (BMI) of 35 or less
  • Phase 1: Single treatable joint surface lesion, ICRS Grade 3 or 4, on medial or lateral femoral condyle
  • Phase 1: Symptomatic single treatable area of 1 to 3.8 cm²
  • Phase 1: Knee Injury and Osteoarthritis Outcome Score (KOOS) pain subscale between 20 and 65
  • Phase 1: Stable knee
  • Phase 1: No improvement after at least 3 weeks of conservative treatment with NSAIDs and/or physical therapy
  • Phase 2: Up to three treatable joint surface lesions, ICRS Grade 3 or 4, on medial or lateral femoral condyles
  • Phase 2: Symptomatic total treatable area of 1 to 10 cm²
  • Phase 2: KOOS pain subscale between 20 and 65
  • Phase 2: Stable knee
  • Phase 2: No improvement after at least 3 weeks of conservative treatment with NSAIDs and/or physical therapy
Not Eligible

You will not qualify if you...

  • Allergy to polyurethanes, bone cement, acrylic, or titanium
  • Less than 2 mm of healthy cartilage or vital bone wall around implant site
  • Osteochondral defect deeper than 11 mm from adjacent surface
  • Bipolar cartilage lesions involving patellar or tibial lesions, ICRS Grade 3 or 4 opposite treatment site
  • Insufficient bone stock or density preventing implant press fit
  • Kellgren and Lawrence grade 3 or 4 on standing radiographs
  • Hip-knee-ankle angle greater than +/- 5 degrees (malalignment)
  • Non-functioning contralateral knee limiting activity
  • Femoral condyle or tibial plateau insufficiency fracture
  • Recent osteochondritis dissecans within 1 year
  • Other knee injuries that may interfere with study participation or outcomes
  • Systemic cartilage or bone disorders like osteoporosis, chondrodysplasia, or osteogenesis imperfecta
  • Symptomatic musculoskeletal conditions affecting lower limbs
  • Known tumor in treatment knee
  • Prior radiation therapy to the knee joint
  • Significant vascular or neurological disorders affecting gait or function
  • Untreated ACL/PCL deficiency or complex ligament instability (IKDC Grade C or D)
  • Knee surgery within past 6 months except diagnostic arthroscopy, debridement, chondroplasty, or meniscectomy
  • Intra-articular injections including hyaluronic acid or steroids within last 3 months

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 2 locations

1

SPORTO

Lodz, Poland, 09-038

Actively Recruiting

2

LIFE Medical Center

Warsaw, Poland, 00-855

Actively Recruiting

Loading map...

Research Team

C

Chris Cain

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

NA

Model

SINGLE_GROUP

Primary Purpose

TREATMENT

Number of Arms

1

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here